

Updates in Surgery

Angelo Di Giorgio
Enrico Pinto *Editors*
In collaboration with
Paolo Sammartino and Franco Roviello

Treatment of Peritoneal Surface Malignancies

State of the Art and Perspectives



 Springer

Updates in Surgery



Angelo Di Giorgio • Enrico Pinto
Editors

Treatment of Peritoneal Surface Malignancies

State of the Art and Perspectives

In collaboration with
Paolo Sammartino
Franco Roviello

Foreword by
Giorgio De Toma

 Springer

Editors

Angelo Di Giorgio

Department of Surgery “Pietro Valdoni”
Sapienza University of Rome
Rome, Italy

Enrico Pinto

Department of Medical, Surgical,
and Neurological Sciences
University of Siena
Siena, Italy

In collaboration with

Paolo Sammartino and Franco Roviello

The publication and the distribution of this volume have been supported by the Italian Society of Surgery

ISSN 2280-9848

ISBN 978-88-470-5710-4

ISBN 978-88-470-5711-1 (eBook)

DOI 10.1007/978-88-470-5711-1

Springer Milan Dordrecht Heidelberg London New York

Library of Congress Control Number: 2014950060

© Springer-Verlag Italia 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Cover design: eStudio Calamar S.L.

Typesetting: Graphostudio, Milan, Italy

Springer-Verlag Italia S.r.l. – Via Decembrio 28 – I-20137 Milan

Springer is a part of Springer Science+Business Media (www.springer.com)

Foreword

On the basis of the latest epidemiological data, peritoneal surface malignancies (PSM) represent a pathology characterized by a high annual incidence, between those of stomach and colorectal cancer.

The integration of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), variously combined with other adjuvant and neoadjuvant chemotherapeutic regimens, is an example of the increasingly complex care strategy for PSM.

There is a strong rationale behind combining CRS with HIPEC to create a procedure based on the evolutionary history of PSM, once considered to be caused only by locally advanced malignancies of the abdominal cavity free of distant metastases. Over the past 20 years, the consistency of results of this integrated procedure has led to it now being considered the treatment of choice for carcinomatosis from pseudomyxoma peritonei, mesothelioma and, recently, the colon, with low peritoneal spread. Furthermore, the trend in using this procedure is increasingly being applied to treat gastric and ovarian carcinomatosis and rarer forms of peritoneal diseases, such as peritoneal metastases from breast and pancreatic cancer and sarcomatosis.

Experience to date using this treatment modality has identified the most significant prognostic parameters and the most important risk factors associated with the procedure. This monograph is thus based on contributions from some of the major Italian centers devoted to treating PSM. It provides the most significant updates on diagnosis, treatment, and outcomes obtained so far. The text thoroughly summarizes the state of the art on CRS plus HIPEC and identifies future development perspectives on related research.

Rome, September 2014

Giorgio De Toma
President, Italian Society of Surgery

Preface

A variety of tumors originating from intra- or extra-abdominal viscera and, more rarely, from the peritoneal membrane, spread or metastasize to the visceral and parietal peritoneum. The term peritoneal surface malignancy (PSM) encompasses all these forms and thus identifies a heterogeneous family of primary or metastatic tumors with epithelial or mesenchymal origin. The inclusion of various forms of primary and secondary PSM under a unique definition is justified by the substantial uniformity of their clinical evolution within the abdominal and pelvic cavity, leading to production of tumor implants and ascites until fatal obstruction occurs. Prognosis is poor, and palliative therapy has long represented the only treatment option. In the natural history of PSM, evolution can be slow and metastatic development late, so that many forms represent ideal targets for aggressive locoregional therapies.

In the 1980s, Paul Sugarbaker theorized – following countless pharmacokinetic and pharmacodynamic studies – about advantages of the association between maximal surgical cytoreduction [peritonectomy (PRT)], aimed at removing all visible implants, and hyperthermic intraperitoneal chemotherapy (HIPEC), aimed at treating microscopic or millimetric residues. Since the 1990s, this concept has gradually gained acceptance and currently is the intervention of choice for pseudomyxoma peritonei and mesothelioma, but it is also diffusely used to treat carcinomatosis from colorectal, gastric, and ovarian cancer and peritoneal sarcomatosis. For the most common forms of PSM treated with PRT plus HIPEC, experiences available to date consistently show overall results better than or highly competitive with traditional treatment modalities. PSM forms that until two decades ago were considered untreatable surgically and for which progression was fatal within months of diagnosis, today, after appropriate patient selection, are routinely treated with PRT plus HIPEC, resulting in improved patient quality of life and long-term survival rates. The combined procedure achieves acceptable postoperative morbidity and mortality rates in relation to its complexity and duration (median 10 h) similar to those of major abdominal and pelvic surgery.

However, the procedure has limited application considering the high overall incidence of various forms of PSM and is not exempt from criticism. The limited

diffusion of PRT plus HIPEC treatment is related to the long learning curve; availability of relevant human, technical, and economic resources; and skepticism toward its effectiveness, particularly in reference to HIPEC, which is considered potentially risky during the postoperative course. Furthermore, the main criticisms concern the lack of prospective randomized phase III studies to define clearly the role of HIPEC, given that the validity of maximum cytoreduction is accepted worldwide. Indeed, to date, overall results of prospective trials for HIPEC are scarce and heavily criticized for the general treatment approach, lack of homogeneity of surgical techniques, and wide dispersion of enrolled cases. Therefore, results regarding overall significance of this procedure come mainly from multi-institutional studies, reviews, meta-analyses, and studies conducted in single centres with a high volume of PRT plus HIPEC activity. While taking into account the limitations inherent in such studies, the magnitude of experience gained to date reveals the overall trend of results. The great effort made by surgeons, oncologists, and specialized centers dedicated to treating PSM using PRT plus HIPEC has brought about the possibility of successfully treating aggressive locoregional tumors such as PSMs. It now remains for the inevitable upcoming prospective studies to confirm the promising results obtained thus far with this combined treatment modality and to determine the most appropriate ways to address treatment for PSM.

The purpose of this monograph is to provide a summary of the knowledge base supporting the rationale of associating maximum cytoreduction with HIPEC, pathological assessment and diagnostic workup of patients with PSM, surgical and HIPEC techniques, and management results of the most common forms of PSM. In the world that revolves around PSM management, Italy plays a significant role, as demonstrated by case series treated by the various PSM centers in this country and the vast scientific contribution drawn from the literature and from acts of the major international conventions. Collaboration between many of the most important specialized Italian surgeons and treatment centers has helped provide an overall picture that illustrates the state of the art regarding PSM management. The topics discussed, and the opinions, experiences, and conclusions expressed by the various authors of these chapters, provide an in-depth summary of experiences pertaining to the most critical issues and outline goals to be achieved in the coming years through collective and coordinated efforts.

Rome, September 2014

Angelo Di Giorgio
Enrico Pinto

Contents

Part I Background

- 1 Peritoneal Surface Malignancies** 3
Angelo Di Giorgio
- 2 Epidemiology: Extent of the Problem** 5
Simone Sibio, Joseph Maher Fouad Atta, Alessio Impagnatiello,
Bianca Maria Sollazzo, and Daniele Marrelli
- 3 Mechanism of Intraperitoneal Spread of Free Cancer Cells** 15
Giovanni Corso, Daniele Marrelli, and Franco Roviello
- 4 Pathology of Peritoneal Surface Malignancies** 21
Antonio Ciardi and Angelo Di Giorgio
- 5 Classification of Intraperitoneal Spread** 53
Simone Giacomuzzi, Francesca Guerini, Andrea Zanoni,
and Giovanni de Manzoni
- 6 Diagnostic Imaging and Laparoscopy** 69
Franco Iafrate, Maria Ciolina, Costanza Cavallini, Daniele Biacchi,
Enzo Naticchioni, and Andrea Laghi

Part II Treatment

- 7 Prevention and Management of Peritoneal Metastases from
Gastrointestinal Cancer: A Short History of a Paradigm for
Peritoneal Surface Malignancies** 93
Paul H. Sugarbaker

8 Rationale for Integrated Procedures: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined	107
Paolo Sammartino, Fabio Accarpio, Tommaso Cornali Daniele Biacchi, Maurizio Cardi, and Giammaria Fiorentini	
9 Peritonectomy Techniques	129
Angelo Di Giorgio	
10 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Techniques	155
Salvatore Virzi, Domenico Rosario Iusco, Serena Bonomi, and Antonio Grassi	
11 The Role of Surgery	169
Marco Lotti, Fausto Catena, Federico Coccolini, Giorgio Ercolani, Antonio Daniele Pinna, and Luca Ansaloni	
12 The Role of Systemic Chemotherapy	179
Patrizia Trenta, Sara Giovannoni, Emanuela Risi, and Enrico Cortesi	
13 Patient Selection for Treatment	195
Paolo Sammartino, Fabio Accarpio, Bianca Maria Sollazzo, Alessio Impagnatiello, Tommaso Cornali, and Daniele Biacchi	
14 Morbidity and Mortality	207
Antonio Macrì, Francesco Fleres, Eugenio Cucinotta, and Edoardo Saladino	
15 Organizational Problems, Costs, and Data Collection	215
Carlo Vallicelli, Simone Sibio, Maurizio Cardi, Davide Cavaliere, and Giorgio Maria Verdecchia	
Part III Results of Integrated Treatment	
16 Pseudomyxoma Peritonei	227
Marco Vaira, Manuela Robella, Alfredo Mellano, and Michele De Simone	
17 Peritoneal Mesothelioma	243
Marcello Deraco, Dario Baratti, Shigeki Kusamura, Antonello D. Cabras, Federica Perrone, and Nadia Zaffaroni	

18	Peritoneal Carcinomatosis from Gastric Cancer	255
	Franco Roviello, Tommaso Cioppa, Daniele Marrelli, Stefano Caruso, and Enrico Pinto	
19	Peritoneal Carcinomatosis from Colorectal Cancer	271
	Antonio Sommariva and Carlo Riccardo Rossi	
20	Peritoneal Carcinomatosis from Ovarian Cancers	295
	Angelo Di Giorgio, Paolo Sammartino, and Pierandrea De Iaco	
21	Other Primary Peritoneal Surface Malignancies	329
	Paolo Sammartino, Fabio Accarpio, Tommaso Cornali, Alessio Impagnatiello, Bianca Maria Sollazzo, and Maria Luisa Framarino dei Malatesta	
22	Other Secondary Peritoneal Surface Malignancies	339
	Maurizio Cardi, Joseph Maher Fouad Atta, Valentina Mingarelli, Enzo Naticchioni, Daniele Biacchi, and Angelo Di Giorgio	
23	Palliative Treatments	349
	Simone Sibio, Joseph Maher Fouad Atta, Daniele Biacchi, Enzo Naticchioni, and Maurizio Cardi	
Part IV Perspectives		
24	Main Topics of Discussion and New Trends	363
	Angelo Di Giorgio	
25	New Trials	375
	Barbara Costantini, Anna Fagotti, Giulia Montori, Federico Coccolini, Luca Ansaloni, and Giovanni Scambia	

Acknowledgments

The volume editors and the publisher gratefully acknowledge the educational contribution offered by Medica S.p.A.

Special thanks to:

Dr. Vittorio Fornasari for the drawings of Chapter 9 and Bernardo Luraschi for the drawings of Chapters 10 and 24;

Section of Iconography of Department of Surgery “Pietro Valdoni”, Sapienza University of Rome for technical assistance.

Contributors

Fabio Accarpio Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Luca Ansaloni Department of General and Emergency Surgery, “Papa Giovanni XXIII” Hospital, Bergamo, Italy

Joseph Mahler Fouad Atta Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Dario Baratti Department of Surgery, National Cancer Institute, Milan, Italy

Daniele Biacchi Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Serena Bonomi General Surgery Unit, Bentivoglio Hospital, Bentivoglio (BO), Italy

Antonello D. Cabras Department of Pathology and Laboratory Medicine, National Cancer Institute, Milan, Italy

Maurizio Cardi Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Stefano Caruso Department of Medical, Surgical and Neurological Sciences, General and Oncologic Surgery Unit, University of Siena, Siena, Italy

Fausto Catena Department of General Surgery, Parma University Hospital, Parma, Italy

Davide Cavaliere Department of Surgery and Advanced Oncologic Therapies, “G.B. Morgagni – L. Pierantoni” Hospital, Forlì, Italy

Costanza Cavallini Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

Antonio Ciardi Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

Maria Ciolina Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

Tommaso Cioppa Doctoral School of Genetics, Oncology, and Clinical Medicine (GenOMec), University of Siena, Italy

Federico Coccolini Department of General and Emergency Surgery, “Papa Giovanni XXIII” Hospital, Bergamo, Italy

Tommaso Cornali Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Giovanni Corso Department of Experimental Oncology, European Institute of Oncology, Milan, Italy

Enrico Cortesi Department of Radiology, Oncology, and Human Pathology, Oncology Unit, Sapienza University of Rome, Rome, Italy

Barbara Costantini Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Catholic University of Sacred Heart, Rome, Italy

Eugenio Cucinotta Department of Human Pathology, University of Messina, Messina, Italy

Pierandrea De Iaco Department of Oncologic Gynecology, “S. Orsola - Malpighi” University Hospital, Bologna, Italy

Giovanni de Manzoni Department of Surgery, Upper G.I. Surgery Unit, Borgo Trento Hospital, Verona, Italy

Marcello Deraco Department of Surgery, National Cancer Institute, Milan, Italy

Michele De Simone Oncology Surgery Unit, Candiolo Cancer Institute, Candiolo (TO), Italy

Angelo Di Giorgio Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Giorgio Ercolani Department of General Surgery, “Sant’Orsola-Malpighi” University Hospital, Bologna, Italy

Anna Fagotti Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Catholic University of Sacred Heart, Rome, Italy

Giammaria Fiorentini Department of Oncology and Hematology, “Ospedali Riuniti Marche Nord” Hospital, Pesaro, Italy

Francesco Fleres Department of Human Pathology, University of Messina, Messina, Italy

Maria Luisa Framarino dei Malatesta Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Franco Iafrate Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

Simone Giacomuzzi Department of Surgery, Upper G.I. Surgery Unit, Borgo Trento Hospital, Verona, Italy

Sara Giovannoni Department of Radiology, Oncology, and Human Pathology, Oncology Unit, Sapienza University of Rome, Rome, Italy

Antonio Grassi General Surgery Unit, Bentivoglio Hospital, Bentivoglio (BO), Italy

Francesca Guerini Department of Surgery, Upper G.I. Surgery Unit, Borgo Trento Hospital, Verona, Italy

Alessio Impagnatiello Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Domenico Rosario Iusco General Surgery Unit, Bentivoglio Hospital, Bentivoglio (BO), Italy

Shigeki Kusamura Department of Surgery, National Cancer Institute, Milan, Italy

Andrea Laghi Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

Marco Lotti Department of General and Emergency Surgery, “Papa Giovanni XXIII” Hospital, Bergamo, Italy

Antonio Macrì Department of Human Pathology, University of Messina, Messina, Italy

Daniele Marrelli Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Alfredo Mellano Oncology Surgery Unit, Candiolo Cancer Institute, Candiolo (TO), Italy

Valentina Mingarelli Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Giulia Montori Department of General and Emergency Surgery, “Papa Giovanni XXIII” Hospital, Bergamo, Italy

Enzo Naticchioni Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

Antonio Daniele Pinna Department of General Surgery, “Sant’Orsola-Malpighi” University Hospital, Bologna, Italy

Enrico Pinto Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

Emanuela Risi Department of Radiology, Oncology, and Human Pathology, Oncology Unit, Sapienza University of Rome, Rome, Italy

- Manuela Robella** Oncology Surgery Unit, Candiolo Cancer Institute, Candiolo (TO), Italy
- Carlo Riccardo Rossi** Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, Padua; Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy
- Franco Roviello** Department of Medical, Surgical, and Neurological Sciences, General and Oncologic Surgery Unit, University of Siena, Siena, Italy
- Edoardo Saladino** Department of Human Pathology, University of Messina, Messina, Italy
- Paolo Sammartino** Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy
- Giovanni Scambia** Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Catholic University of Sacred Heart, Rome, Italy
- Simone Sibio** Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy
- Bianca Maria Sollazzo** Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy
- Antonio Sommariva** Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, Padua, Italy
- Paul H. Sugarbaker** Center for Gastrointestinal Malignancies, Washington Cancer Institute, Washington, DC, USA
- Patrizia Trenta** Department of Radiology, Oncology, and Human Pathology, Oncology Unit, Sapienza University of Rome, Rome, Italy
- Marco Vaira** Oncology Surgery Unit, Candiolo Cancer Institute, Candiolo (TO), Italy
- Carlo Vallicelli** Department of Surgery and Advanced Oncologic Therapies, “G.B. Morgagni – L. Pierantoni” Hospital, Forlì, Italy
- Giorgio Maria Verdicchia** Department of Surgery and Advanced Oncologic Therapies, “G.B. Morgagni – L. Pierantoni” Hospital, Forlì, Italy
- Salvatore Virzì** General Surgery Unit, Bentivoglio Hospital, Bentivoglio (BO), Italy
- Nadia Zaffaroni** Department of Experimental Oncology and Molecular Medicine, Molecular Pharmacology Unit, National Cancer Institute, Milan, Italy
- Andrea Zanoni** Department of Surgery, Upper G.I. Surgery Unit, Borgo Trento Hospital, Verona, Italy